Innovent Biologics, Inc. (HKG:1801)

Market Cap	77.88B
Revenue (ttm)	10.03B
Net Income (ttm)	-100.70M
Shares Out	1.65B
EPS (ttm)	-0.06
PE Ratio	n/a
Forward PE	194.04
Dividend	n/a
Ex-Dividend Date	n/a

Volume	12,569,706
Average Volume	25,906,495
Open	46.20
Previous Close	46.15
Day's Range	45.30 - 47.80
52-Week Range	28.65 - 52.15
Beta	0.31
RSI	57.23
Earnings Date	Mar 25, 2025

About Innovent Biologics

Innovent Biologics, Inc., a biopharmaceutical company, develops and commercializes monoclonal antibodies and other drug assets in the fields of oncology, ophthalmology, autoimmune, and cardiovascular and metabolic diseases in the People’s Republic of China. It offers Tyvyt, a human anti-PD-1 monoclonal antibody; BYVASDA, a fully-human anti-VEGF monoclonal antibody; HALPRYZA, a recombinant chimeric murine/human anti-CD20 monoclonal antibody; SULINNO, a fully-human antiTNF-α monoclonal antibody; Pemazyre, a selective FGFR inhibitor; Olverembatini...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2011
• Employees: 5,659
• Stock Exchange: Hong Kong Stock Exchange
• Ticker Symbol: 1801

Financial Performance

In 2024, Innovent Biologics's revenue was 9.42 billion, an increase of 51.82% compared to the previous year's 6.21 billion. Losses were -94.63 million, -90.79% less than in 2023.

Financial numbers in CNY